CD274 and neoplasm: Given the favorable toxicity profile of RRx-001 and since both CD-47 and PD-L1 serve as innate and adaptive checkpoints, respectively, it was hypothesized that the combination of RRx-001 and nivolumab would be well-tolerated and potentially active in tumor types that were traditionally non-CI-responsive due to the broadness of induced innate and adaptive immune stimulation against target tumors.